4.5 Multiple Sclerosis & Demyelinating Disease Rehabilitation

Multiple Sclerosis & Demyelinating Disease Rehabilitation

Multiple sclerosis (MS) is a recurrent Domain C neurological condition. The physiatrist manages disability across relapsing and progressive phenotypes through interdisciplinary symptom control, exercise, and assistive technology while disease-modifying therapy is handled by neurology.

Diagnosis & Phenotypes

MS is diagnosed by dissemination of CNS demyelinating lesions in space and time, per McDonald criteria, using MRI (periventricular, juxtacortical, infratentorial, spinal cord plaques) and CSF (oligoclonal bands) or typical clinical attacks. Phenotypes:

Disease-Modifying Therapy (Neurology-Led)

• Injectables: interferon beta, glatiramer acetate.
• Monoclonal antibodies: natalizumab (anti-alpha-4 integrin; PML risk with JC virus), ocrelizumab/rituximab (anti-CD20; used in RRMS and PPMS), alemtuzumab.
• Orals: fingolimod, dimethyl fumarate, teriflunomide, siponimod. Rehab does not substitute for DMT; the physiatrist reinforces adherence and monitors for complications (e.g., PML surveillance).

Symptom Management (Rehab Core)

Exercise & Rehabilitation

Fatigue + Deconditioning  ──►  ↓Activity  ──►  Further Deconditioning (Vicious Cycle)
        │
        └── Graded Moderate Aerobic + Resistance Exercise ──► ↑Mobility, ↓Fatigue, ↑QoL, ↑Cognition

Evidence supports moderate-intensity aerobic (e.g., 20-30 min, 3-5x/week) and resistance training in MS, improving fatigue, mobility, and quality of life without exacerbating disease. Heat intolerance (Uhthoff phenomenon) is managed with pre-cooling, indoor activity, and hydration. Resistive exercise is progressed gradually; relapse management temporarily reduces intensity. FES cycling and peroneal nerve stimulators address foot drop and disuse.

Disease Course, Prognosis & Red Flags

MS prognosis is variable; favorable factors include relapsing-remitting course, female sex, young onset, sensory presentation, and infrequent relapses. Poor prognosis correlates with male sex, primary progressive course, early cerebellar/pyramidal involvement, and high early lesion burden. The physiatrist should recognize red flags requiring urgent neurology: acute relapse vs pseudo-relapse (fever, infection—urinary tract infection is the most common trigger of pseudo-relapse—must be excluded before treating a relapse), progressive multifocal leukoencephalopathy on natalizumab (new neurologic deficits, JC virus positivity), and treatment-related CNS infections.

Cognition, Mood & Employment

Cognitive impairment affects 40-70% of MS patients, predominantly information processing speed, attention, and executive function, and is a leading cause of employment cessation independent of physical disability. Depression prevalence is high and bidirectional with fatigue and disability. Rehabilitation addresses cognition with compensatory strategies, occupational therapy for workplace accommodation, and screening/management of depression and anxiety—anxiety is often under-recognized and contributes to fatigue and reduced participation.

Interdisciplinary Team & Goal Setting

Physiatrist (spasticity, mobility, symptom mgmt) ──┐
Neurology (DMT, relapse mgmt) ─────────────────────┤
PT (gait, balance, strength) ──────────────────────┤──► Patient-Centered Goals
OT (ADLs, upper-limb, cognition, work) ─────────────┤    (FIM, EDSS, MSIS-29)
Speech (dysarthria, dysphagia, cognition) ─────────┤
Urology / Nursing (bladder-bowel program) ──────────┤
Psychology / Neuropsych (cognition, mood) ──────────┘

Goal setting uses validated measures: the Expanded Disability Status Scale (EDSS, 0-10, weighted heavily on ambulation), MSIS-29, and FIM. Ambulation-based EDSS transitions drive assistive-device and DMT decisions.

Heat, Fatigue & Lifestyle

Beyond Uhthoff management, fatigue in MS is multifactorial (central, motor, deconditioning, depression, sleep disturbance, medication). Pre-cooling, pacing/energy conservation, treating reversible contributors (anemia, thyroid, sleep apnea, depression), and graded exercise all contribute. Smoking cessation and vitamin D adequacy are associated with better outcomes. The physiatrist coordinates these lifestyle and medical levers with the neurology-led DMT plan.

Demyelinating Differentials: NMOSD & MOGAD

Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are distinct demyelinating entities the physiatrist must distinguish from MS because they preferentially attack the optic nerve and spinal cord, classically as longitudinally extensive transverse myelitis spanning three or more vertebral segments, and carry different prognostic and rehabilitation implications. AQP4-IgG-seropositive NMOSD is often more aggressive, with severe optic neuritis and myelitis and a higher relapse-related disability burden; MOGAD generally shows better recovery after individual attacks. Rehabilitation parallels MS—spasticity, neurogenic bladder and bowel, neuropathic pain, mobility loss, and assistive-technology needs—but the physiatrist should avoid attributing new deficits to MS progression without neurology review, since misphenotyping alters disease-modifying treatment. With cervical lesions, pressure-injury prevention and autonomic dysreflexia surveillance are essential.

EDSS Ambulation Milestones

The Expanded Disability Status Scale anchors rehab planning to ambulation, and knowing the milestones drives assistive-device prescription: EDSS 4.0 ambulates at least 500 m without aid or rest, 4.5 at least 300 m, 5.0 about 200 m without aid or rest, 5.5 about 100 m, 6.0 requires unilateral aid (cane or crutch) for 100 m, 6.5 requires bilateral aids for about 20 m, and 7.0 restricts the patient to a wheelchair. Crossing these thresholds objectively triggers cane, walker, or wheelchair prescription, home-exercise progression, and goal-of-care conversations.